Drug-resistant HIV infection among drug-naive patients in Israel

Clinical Infectious Diseases

Volumn 40, Issue 2, 2005, Pages 294-302

  Grossman, Z ^a,b   Lorber, M ^d   Maayan, S ^e   Bar Yacov, N ^f   Levy, I ^b   Averbuch, D ^e   Istomin, V ^g   Chowers, M ^h   Sthoeger, Z ⁱ   Ram, D ^a   Rudich, H ^a   Mileguir, F ^a   Pavel, R ^a   Almaliach, R ^a,k   Schlaeffer, F ^j   Kra Oz, Z ^d   Mendelson, E ^a,k   Schapiro, J M ^c   Riesenberg, K ^j  

^a Public Health Laboratories   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c National Hemophilia Center   (Israel)

^d RAMBAM MEDICAL CENTER   (Israel)

^e HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^f TEL AVIV UNIVERSITY   (Israel)

^g HILLEL YAFFE MEDICAL CENTER   (Israel)

^h MEIR MEDICAL CENTER   (Israel)

ⁱ KAPLAN MEDICAL CENTER   (Israel)

^j BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^k BAR ILAN UNIVERSITY   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISRAEL; MALE; MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HUMANS; ISRAEL; MALE; MUTATION; PHYLOGENY; POLYMORPHISM, GENETIC; RNA, VIRAL; RNA-DIRECTED DNA POLYMERASE;

EID: 19944429038     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/426592     Document Type: Article

References (36)

1. Yerly S, Rakik A, Kinloch-de-Loes S, et al. Prevalence of transmission of zidovudine-resistant viruses in Switzerland. l'Etude suisse de cohorte VIH [in French]. Schweiz Med Wochenschr 1996; 126:1845-8.
2. Brodine SK, Shaffer RA, Starkey MJ, et al. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med 1999; 131:502-6.
3. Sugiura W, Matsuda M, Abumi H, et al. Prevalence of drug resistance-related mutations among HIV-1s in Japan. Jpn J Infect Dis 1999; 52:21-2.
4. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999; 354:729-33.
5. Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999; 282:1142-9.
6. Puig T, Perez-Olmeda M, Rubio A, et al. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group. AIDS 2000; 14:727-32.
7. Salomon H, Wainberg MA, Brenner B, et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 2000; 14:F17-23.
8. Weinstock H, Respess R, Heneine W, et al. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998. J Infect Dis 2000; 182:330-3.
9. Wegner SA, Brodine SK, Mascola JR, et al. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. AIDS 2000; 14:1009-15.
10. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001; 322:1087-8.
11. Tanuri A, Caridea E, Dantas MC, et al. Prevalence of mutations related to HIV-1 antiretroviral resistance in Brazilian patients failing HAART. J Clin Virol 2002; 25:39-46.
12. Yerly S, Vora S, Rizzardi P, et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15:2287-92.
13. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-94.
14. Hanna GJ, Balaguera HU, Freedberg KA, et al. Drug-selected resistance mutations and non-B subtypes in antiretroviral-naive adults with established human immunodeficiency virus infection. J Infect Dis 2003; 188:986-91.
15. Wensing AM, Boucher CA. Worldwide transmission of drug-resistant HIV. AIDS Rev 2003; 5:140-55.
16. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998; 279:1977-83.
17. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195-9.
18. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002; 288:222-35.
19. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Rockville, MD: US Department of Health and Human Services, 2003. Available at: http://aidsinfo.nih.gov/guidelines. Accessed 23 March 2004.
20. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37:113-28.
21. Chemtob D, Grossman Z. Epidemiology of adult and adolescent HIV infection in Israel - a country of immigration. Int J STD AIDS 2004; 15:691-6.
22. Statistical abstract of Israel. Jerusalem: The State of Israel, Central Bureau of Statistics, 2001. Available at: http://wwwl.cbs.gov.il/.
23. Adler MW. ABC of AIDS-development of the epidemic. BMJ 2001; 322:1226-9.
24. Kantor R, Machekano R, Gonzales MJ, Dupnik K, Schapiro JM, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res 2001; 29:296-9.
25. Kuiken C, Korber B, Shafer RW. HIV sequence databases. AIDS Rev 2003; 5:52-61.
26. Wu TD, Schiffer CA, Gonzales MJ, et al. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol 2003; 77:4836-47.
27. Wensing AMJ, van de Vijver DAMC, Asjo B, et al. Prevalence of transmitted drug resistance in Europe is largely influenced by the presence of non-B sequences: analysis of 1400 patients from 16 countries: the CATCH-Study [abstract 117]. Antiviral Ther 2003;8:S131.
28. Grossman Z, Vardinon N, Chemtob D, et al. Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS 2001; 15:1453-60.
29. Pieniazek D, Rayfield M, Hu DJ, et al. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. AIDS 2000; 14:1489-95.
30. Cane PA, de Ruiter A, Rice P, Wiselka M, Fox R, Pillay D. Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom. J Clin Microbiol 2001; 39:2652-4.
31. Kantor R, Carvalho AP, Wynhoven B, et al. Nucleic acid differences between HIV-1 non-B and B reverse transcriptase and protease sequences at drug resistance positions [abstract 53]. Antiviral Ther 2003;8(Suppl 58):S58.
32. Kantor R, Zijenah LS, Shafer RW, et al. HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 2002; 18:1407-13.
33. Los Alamos HIV sequence database: drug resistance alignments. Los Alamos, NM: Los Alamos National Laboratory, 2004.
34. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22:4673-80.
35. Wensing AMJ, van de Vijver DAMC, Asjo B, et al. Analysis from more than 1600 newly diagnosed patients with HIV from 17 European countries shows that 10% of the patients carry primary drug resistance: the CATCH-study [abstract LB 1 ]. In: Proceedings of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment (Paris), 2003.
36. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001; 134:440-50.